The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?

Abroad (travel likely)Recruiting

Conditions

Brain Metastases · Nsclc

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University Hospital of Heidelberg, Radiation Oncology, Heidelberg, Germany
Contact: Study coordinator (Jürgen Debus, Prof. Dr.) · juergen.debus@med.uni-heidelberg.de · +49-6221-56
Contact: Study coordinator (Adriane Hommertgen) · adriane.hommertgen@med.uni-heidelberg.de · +49-6221-56

Study leads

Juergen Debus, Prof.
Principal Investigator
Head of Department

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

Brain Metastases From Non-small Cell Lung Cancer (NSCLC) · Brain Metastases From Melanoma · Brain Metastases From Breast Cancer

Abroad (travel likely)Recruiting

Amsterdam, Netherlands

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

NSCLC · Brain Metastases · ROS1 Gene Rearrangement

Abroad (travel likely)RecruitingPHASE2

Graz, Austria · Vienna, Austria

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Brain Metastases · Nonsmall Cell Lung Cancer Stage III

Abroad (travel likely)RecruitingPHASE2

Winston-Salem, United States

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Melanoma · Brain Metastases

Abroad (travel likely)RecruitingPHASE2

Palo Alto, United States